Azitra is trading at $0.13 (down 6.2%) as it faces continued selling pressure driven by delisting risks and broader biotech sector weakness.
- The stock is currently under NYSE American non-compliance, heightening concerns over potential delisting and prior financing volatility.
- Shares remain highly volatile with weak fundamentals contributing to a sustained downward trend.
- A broader downturn in the biotechnology sector today is further weighing on investor sentiment and driving the current slide.